Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route

Area of Science:

• Pharmacology
• Nanotechnology
• Neuroscience

Background:

• Intranasal drug delivery offers a potential route to bypass the blood-brain barrier (BBB).
• Risperidone (RSP) is an antipsychotic medication with limited brain penetration.
• Solid lipid nanoparticles (SLNs) are a promising drug delivery system for enhanced therapeutic outcomes.

Purpose of the Study:

• To formulate and characterize risperidone-loaded solid lipid nanoparticles (RSLNs).
• To investigate the potential of RSLNs for direct nose-to-brain delivery.
• To evaluate the brain targeting efficiency of RSLNs compared to conventional administration routes.

Main Methods:

• RSLNs were prepared using the solvent emulsification-solvent evaporation method.
• Characterization included drug content, particle size, zeta potential, and in vitro drug release.
• Pharmacodynamic, pharmacokinetic, biodistribution, and gamma scintigraphy studies were conducted in mice.

Main Results:

• RSLNs exhibited favorable physicochemical properties and controlled in vitro drug release.
• Pharmacodynamic studies showed superior brain targeting of RSLNs via intranasal administration.
• Pharmacokinetic data revealed significantly higher brain/blood ratios for intranasal RSLNs compared to intravenous routes.

Conclusions:

• Intranasal administration of RSLNs provides an effective strategy for direct nose-to-brain drug delivery.
• RSLNs enhance risperidone brain targeting, overcoming the limitations of the blood-brain barrier.
• This study validates the nose-to-brain pathway for nanoparticle-based drug delivery to the brain.